Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Activating mutations of EZH2, an epigenetic regulator, are present in 20% of follicular lymphoma patients. Tazemetostat monotherapy showed clinically...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
